Is SHC a good stock to buy? We came across a bullish thesis on Sotera Health Company on Valueinvestorsclub.com by AZA0601. In this article, we will summarize the bulls’ thesis on SHC. Sotera Health Company’s share was trading at $17.10 as of June 25th. SHC’s trailing and forward P/E were 41.71 and 17.27 respectively according to Yahoo Finance.
Copyright: katrintimoff / 123RF Stock Photo
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. SHC is an approximately $6 billion enterprise value end-to-end provider of sterilization solutions primarily to medtech and some pharma customers, operating a critical outsourced step where products are sterilized at its facilities before returning to manufacturers. Historically backed by GTCR and Warburg Pincus, sponsor ownership has declined from ~60% post-IPO to ~11%, reducing a persistent overhang.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Despite solid underlying performance, revenue has grown from $818 million to $1.16 billion (~7% CAGR) and EBITDA from $420 million to $594 million, the stock has underperformed due to litigation, regulatory concerns, and perception issues, compressing valuation from ~20x to ~10x EBITDA. The business is fundamentally high quality, with duopoly positions across ~80% of Sterigenics operations, >90% multi-year contracts, near-perfect retention among top customers, and structurally high switching costs supported by FDA registrations, enabling sustained mid-to-high single-digit pricing power and high-50% EBITDA margins.
The investment case is reinforced by accelerating industry tailwinds from rising medtech outsourcing and tightening EPA emissions standards that raise barriers to entry and are forcing smaller competitors to exit, driving capacity constraints and pricing upside. Litigation risk, previously a major discount driver, has been steadily de-risked through settlements at declining per-plaintiff costs, while remaining cases appear limited and increasingly manageable.
Management guidance of 5–7% organic growth is viewed as conservative versus peer disclosures and underlying demand dynamics, suggesting upside to both pricing and volume. With one-time investments rolling off, Sotera is positioned for a free cash flow inflection and deleveraging followed by buybacks. At ~12x EBITDA less capex, valuation points to ~$30 per share versus ~$16 today implying ~25% 3-year IRR with further upside from regulation, consolidation, and pricing strength.
Previously, we covered a bullish thesis on Danaher Corporation (DHR) by Best Anchor Stocks in May 2025, which highlighted resilient bioprocessing recovery, conservative guidance, and strong buyback-driven capital allocation supporting steady compounding. DHR’s stock price has depreciated by approximately 1.77% since our coverage. AZA0601 shares a similar view but emphasizes valuation rerating and structural tailwinds in Sotera Health.
Sotera Health Company is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held SHC at the end of the first quarter which was 41 in the previous quarter. While we acknowledge the risk and potential of SHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SHC and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
